Polyrizon Stock Soars 10.56% on Epilepsy Treatment Breakthrough

On March 26, 2025, Polyrizon's stock surged by 10.56% in pre-market trading, reflecting a significant upward momentum.

Polyrizon has made substantial strides in its drug delivery innovation, particularly in the field of epilepsy treatment. The company has launched a preclinical program aimed at improving emergency treatment options for epilepsy patients. This initiative is part of a broader effort to revolutionize emergency epilepsy care, targeting a $3.15 billion market opportunity with its proprietary intranasal seizure treatment platform.

Despite a notable decrease earlier in the day, Polyrizon's stock showed a significant recovery in the after-hours session. This recovery can be attributed to the positive news surrounding the company's preclinical studies for epilepsy rescue treatment, which has garnered attention and investor interest.